VectorY Therapeutics appoints Jim Scibetta as CEO to lead development of VTx-002, a vectorized antibody therapy targeting TDP ...
VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback